Navigation Links
CCNY chemists devise new way to prepare molecules for drug testing
Date:8/15/2013

James Bond had his reasons for ordering his martinis "shaken, not stirred." Similarly, drug manufacturers need to make sure the molecules in a new drug are arranged in an exact manner, lest there be dire consequences. Specifically, they need to be wary of enantiomers, mirror-image molecules composed of the same atoms, but arranged differently.

"One mirror image could be therapeutic while another could be poisonous," said Dr. Mark R. Biscoe, assistant professor of chemistry at The City College of New York. The classic case is thalidomide, a drug marketed in the 1950s and 1960s to treat morning sickness, which resulted in serious birth defects.

Professor Biscoe led a team of researchers at CCNY that developed a new method for preparing libraries of single-enantiomer molecules for therapeutic and toxicity studies that is faster and potentially less costly than methods now used in the pharmaceutical industry. Their findings were reported in Nature Chemistry.

Currently, drug developers typically rely on a chiral resolution process whereby compounds with roughly equal parts of the two enantiomers are separated into the individual enantiomers. Bioenzymatic processes can also be employed to generate single-enantiomer molecules. These strategies are wasteful and costly, Professor Biscoe explained.

He and colleagues found that a metal such as palladium could be employed to achieve a cross-coupling reaction with a single-enantiomer molecule without impacting the integrity of the mirror image formed in the product. By doing so, they could isolate one mirror image for evaluation as a drug candidate.

"By using a single-enantiomer partner in a cross-coupling reaction, we can rapidly generate a diverse library of biologically active molecules for use in drug screening," he said.


'/>"/>

Contact: Ellis Simon
esimon@ccny.cuny.edu
212-650-6460
City College of New York
Source:Eurekalert

Page: 1

Related biology news :

1. UC Berkeley chemists installing first carbon dioxide sensor network in Oakland
2. UMass Amherst biochemists developing tools to stop plague and other bacterial threats
3. Chemists advance clear conductive thin films
4. Chemists develop reversible method of tagging proteins
5. Chemists devise inexpensive, benchtop method for marking and selecting cells
6. UCI chemists devise inexpensive, accurate way to detect prostate cancer
7. University of Wisconsin chemists find new compounds to curb staph infection
8. Biochemists uphold law of physics
9. Lizard moms may prepare their babies for a stressful world
10. No need to prepare
11. Stowers study hints that stem cells prepare for maturity much earlier than anticipated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 BioCatch, the global ... today it has been named in Gartner,s Market Guide ... replaces Gartner,s well-known Magic Quadrant for Web Fraud Detection. ... one of several vendors to deliver passive biometric analysis ... a standard feature of at least 30% of one-stop ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... International Journal of Fuzzy Systems ( IJFS ), ... (TFSA). The cooperation will allow the journal to expand ... The International Journal of Fuzzy Systems is ... theory, design and application of fuzzy systems, soft computing ... hardware to software. Launched in 1999, the quarterly journal ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... WALTHAM, MA April 1, 2011 Avila ... drugs, today announced the publication of a scientific ... titled "The Resurgence of Covalent Drugs" ( www.nature.com/reviews/drugdisc , ... discusses the broad opportunities for covalent drugs and how ...
... never good for you, but washing that meal down with ... of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not ... eating a high-fat meal, but that the spike doubles after ... to levels similar to those of people at risk for ...
... muscle strength. Not only can adults fight the battle ... Golden Years can be a time to get stronger, say experts ... exercise is a great way to increase lean muscle tissue and ... life," says Mark Peterson, Ph.D., a research fellow in the U-M ...
Cached Biology News:New opportunities for covalent drugs published by Avila scientists 2Got a craving for fast food? Skip the coffee, study says 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 3Older and stronger: Progressive resistance training can build muscle, increase strength as we age 4
(Date:7/23/2014)... July 23, 2014  Sangamo BioSciences, Inc. (NASDAQ: ... financial results and accomplishments. For the ... consolidated net loss of $7.0 million, or $0.10 per ... or $0.10 per share, for the same period in ... cash, cash equivalents, marketable securities and interest receivable of ...
(Date:7/23/2014)... SKOKIE, Ill. , July 23, 2014 ... acid (SNA™) constructs as gene regulatory and ... Snyder has joined AuraSense Therapeutics, executive ... July 11. Prior to joining ... President and Chief Financial Officer of Cellular ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 StemGenex® ... therapy in the US aimed at improving the lives ... newest clinical study for Parkinson’s disease. StemGenex believes ... stem cell therapy are paramount when providing care to ... study makes stem cell therapy accessible to the millions ...
(Date:7/23/2014)... July 23, 2014 Shire ... the global specialty biopharmaceutical company, and ArmaGen, a ... worldwide licensing and collaboration agreement for AGT-182, an ... treatment of both the central nervous system (CNS) ... (MPS II). This collaboration strengthens Shire,s rare disease ...
Breaking Biology Technology:Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... BVF Acquisition LLC (the "Purchaser"), an affiliate of Biotechnology Value ... to purchase all of the outstanding shares of Avigen, Inc. ... announced today that it has extended the expiration date for ... on Friday, March 6, 2009. The tender offer was previously ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... ( http://www.cordblood-america.com ) focused on bringing the life ... and internationally, today announced that Matthew Schissler, founder ... Gaskins, provided details of the Company,s special shareholder ...
... Declares 341st Consecutive Quarterly Dividend ABBOTT PARK, Ill., Feb. ... ABT ) today increased the company,s quarterly common dividend 11 ... consecutive year that Abbott has increased its dividend payout and ... since 1924. The cash dividend is payable May 15, ...
Cached Biology Technology:BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009 2BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009 3In Analyst Interview, Cord Blood America Provides Details of Special Shareholder Meeting 2
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
...
... CELSR3 is an Orphan-U GPCR with an ... expressed during development at sites of active neurogenesis ... spinal cord, dorsal root ganglion, and eye. ESTs ... colon, heart/melanocyte/uterus, lung, nerve, and placenta libraries. ...
Biology Products: